iBio (IBIO) news
Recent news
IBIO Inc <IBIO.O>: B. Riley initiates coverage with buy rating; target price $6
B. Riley Securities has initiated coverage of iBio, Inc. (IBIO.O) with a "Buy" rating and a target price of $6.00, signaling optimism about the company’s long-term potential. iBio is a preclinical biotechnology firm utilizing AI to develop precision antibodies for challenging diseases, including…
AInvest Wire · Jun 5, 2026iBio amends and extends maturity of credit pact
iBio amends and extends maturity of credit pact iBio, a company focused on AI-driven precision antibody immunotherapies, recently announced an amendment to its credit agreement with Woodforest National Bank [1]. The amendment extends the maturity date of the credit agreement from November 1, 2023,…
AInvest Wire · Dec 26, 2023ImportantiBio shares sink 40% after announcing pricing of $4.5M public offering
AInvest Wire · Dec 5, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.